权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Protein Sequencing Tools for Biological Therapeutics

用于生物治疗的蛋白质测序工具

基本信息

批准号：
8979388
负责人：
David Fenyo
金额：
$ 49.44万
依托单位：
PROTEIN METRICS, LLC
依托单位国家：
美国
项目类别：
财政年份：
2012
资助国家：
美国
起止时间：
2012-09-03 至 2017-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8979388
关键词：
Address Algorithms Amino Acid Sequence Amino Acid Sequence Databases Antibodies Antigens Area Biological Charge Collaborations Complementarity Determining Regions Complex Mixtures Computer software Cysteine Data Data Analyses Databases Development Digestion Engineering Environment Enzymes Experimental Designs Goals HIV HLA Antigens Health Hormones Human Hybridomas Imagery Immunoglobulin G Immunoglobulin Variable Region Individual Laboratories MHC Class I Genes Malaria Malignant Neoplasms Manuals Mass Spectrum Analysis Methods Monoclonal Antibodies Neurotoxins Organism Patients Peptide Sequence Determination Peptide antibodies Peptide/MHC Complex Peptides Pharmaceutical Preparations Phase Plants Post-Translational Protein Processing Price Proteins Proteomics Reading Frames Recombinants Reporting Research Rest Running Sales Sampling Scorpion Venoms Small Business Technology Transfer Research Snail Venoms Solutions Spider Venoms System Techniques Testing Therapeutic Therapeutic Monoclonal Antibodies Therapeutic antibodies Toxin Validation Work antimicrobial peptide cancer immunotherapy data acquisition falls genome sequencing high throughput analysis improved interest meetings neutralizing antibody next generation sequencing polyclonal antibody protein aminoacid sequence prototype public health relevance response tool transcriptome sequencing vaccine development

项目摘要

DESCRIPTION (provided by applicant): Mass spectrometry has become a method of choice for identifying and characterizing small quantities of proteins in complex mixtures. However, the ability to perform the identification in a high-throughput fashion has depended on the availability of high-quality protein sequence databases. This means that proteins from organisms with unsequenced or poorly sequenced genomes (e.g. peptide toxins) and proteins that modify their primary sequences rapidly in response to the environment (e.g. antibodies) have been excluded from high-throughput analysis. Widespread availability of Next Generation Sequencing (NGS) has not alleviated this problem, but rather NGS has led to a proliferation of lower quality, uncurated protein sequence databases, including personalized databases, cancer databases, and databases with uncertain assembly. The traditional division between database-search proteomics and de novo peptide sequencing no longer holds; many of the most interesting biological questions are now best addressed by data analysis that combines the best of both techniques. In this Phase II STTR project, we propose to develop two commercial software products for sequencing biologically interesting peptides and proteins, regardless of the quality of sequence databases. One product will be aimed at the peptide level, with applications to variable regions of circulating antibodies, peptide toxins, and human leukocyte antigens. The other product will be aimed at the protein level, with applications to end-to-end sequencing of purified proteins, especially therapeutic monoclonal antibodies. This system will include the peptide-level sequencer as a component, as well as tools for assembly of the peptides into the full sequence and for visualization and manual validation. The proposed project has the potential for great impact on human health in areas such as vaccine development, therapeutic antibody development, and cancer immunotherapies.